Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Illumina Inc (ILMN) is a leading diagnostics & research business based in the US. It opened the day at $382.61 after a previous close of $384.24. During the day the price has varied from a low of $380.15 to a high of $385.95. The latest price was $380.44 (25 minute delay). Illumina is listed on the NASDAQ and employs 7,800 staff. All prices are listed in US Dollars.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Open | $382.61 |
|---|---|
| High | $385.95 |
| Low | $380.15 |
| Close | $380.44 |
| Previous close | $384.24 |
| Change | $-3.80 |
| Change % | -0.989% |
| Volume | 413,370 |
| 52-week range | $341.03 - $555.77 |
|---|---|
| 50-day moving average | $380.20 |
| 200-day moving average | $423.79 |
| Wall St. target price | $429.94 |
| PE ratio | 66.3186 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $6.11 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $380.44 from 2022-01-21
| 1 week (2022-01-14) | -6.10% |
|---|---|
| 1 month (2021-12-22) | 0.43% |
| 3 months (2021-10-22) | -7.02% |
| 6 months (2021-07-22) | -21.80% |
| 1 year (2021-01-22) | -6.35% |
|---|---|
| 2 years (2020-01-22) | 14.94% |
| 3 years (2019-01-22) | 25.30% |
| 5 years (2017-01-20) | 138.16% |
Valuing Illumina stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Illumina's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Illumina's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 66x. In other words, Illumina shares trade at around 66x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Illumina's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.9513. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Illumina's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Illumina's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $918 million.
The EBITDA is a measure of a Illumina's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $4.3 billion |
|---|---|
| Operating margin TTM | 16.5% |
| Gross profit TTM | $2.2 billion |
| Return on assets TTM | 3.93% |
| Return on equity TTM | 11.86% |
| Profit margin | 21.19% |
| Book value | $67.47 |
| Market capitalisation | $63.3 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Illumina.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 9.18
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Illumina's overall score of 9.18 (as at 12/31/2018) is excellent – landing it in it in the 2nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Illumina is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 2.22/100
Illumina's environmental score of 2.22 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Illumina is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 2.6/100
Illumina's social score of 2.6 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Illumina is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 5.36/100
Illumina's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Illumina is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Illumina scored a 1 out of 5 for controversy – the highest score possible, reflecting that Illumina has managed to keep its nose clean.
Illumina Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 9.18 |
|---|---|
| Total ESG percentile | 2.42 |
| Environmental score | 2.22 |
| Environmental score percentile | 2 |
| Social score | 2.6 |
| Social score percentile | 2 |
| Governance score | 5.36 |
| Governance score percentile | 2 |
| Level of controversy | 1 |
We're not expecting Illumina to pay a dividend over the next 12 months.
Illumina's shares were split on a 2:1 basis on 22 September 2008. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Illumina shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Illumina shares which in turn could have impacted Illumina's share price.
Over the last 12 months, Illumina's shares have ranged in value from as little as $341.03 up to $555.77. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Illumina's is 0.887. This would suggest that Illumina's shares are less volatile than average (for this exchange).
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has collaboration agreements with Geneseeq Technology Inc.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
Everything we know about the HeartCore Enterprises IPO, plus information on how to buy in.